D. Romero

发表

Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field.

Jennifer L. Knight, Markus K. Dahlgren, Edward D Harder, 2015, Journal of the American Chemical Society.

Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication.

L. Resnick, D. Romero, D L Romero, 1991, Proceedings of the National Academy of Sciences of the United States of America.

U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication

L. Resnick, S. Swaney, D. Romero, 1993, Antimicrobial Agents and Chemotherapy.

Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a s

L. Resnick, D. Romero, C. Biles, 1993, Journal of medicinal chemistry.

Discovery, synthesis, and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors.

D. Romero, C. Biles, D L Romero, 1994, Journal of medicinal chemistry.

Synthesis and bioactivity of novel bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships and increased metabolic stability of novel substituted pyridine analogs.

L. Kopta, R. Olmsted, D. Romero, 1996, Journal of medicinal chemistry.

Discovery, Synthesis, and Bioactivity of Bis(heteroaryl)piperazines. Part 1. A Novel Class of Non‐Nucleoside HIV‐1 Reverse Transcriptase Inhibitors.

Paul D. Johnson, L. Resnick, D. Romero, 2010 .

Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.

B C Finzel, K D Watenpaugh, W. Howe, 1996, Journal of medicinal chemistry.

Chapter 13. Advances in the Development of HIV Reverse Transcriptase Inhibitors

D. Romero, 1994 .

Current HIV therapeutics: mechanistic and chemical determinants of toxicity.

Dale E. Johnson, D. Romero, Stephanie Chiao, 2009, Current opinion in drug discovery & development.

Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.

S. Robinson, D. Romero, D. Chaudhary, 2015, Journal of medicinal chemistry.

Depletion of glutathione by benzo(a)pyrene metabolites, ionomycin, thapsigargin, and phorbol myristate in human peripheral blood mononuclear cells.

F. Lauer, S. Burchiel, B. Mounho, 1997, Toxicology and applied pharmacology.

PAS kinase drives lipogenesis through SREBP-1 maturation.

J. Rutter, B. Zweifel, D. Romero, 2014, Cell reports.

Correlation of carboxylic acid pKa to protein binding and antibacterial activity of a novel class of bacterial translation inhibitors.

D. Romero, M. Zhong, M. T. Sweeney, 2007, Bioorganic & medicinal chemistry letters.

Structure-activity relationships of bioisosteres of a carboxylic acid in a novel class of bacterial translation inhibitors.

K. Marotti, D. Romero, M. T. Sweeney, 2007, Bioorganic & medicinal chemistry letters.

Preparation of novel antibacterial agents. Replacement of the central aromatic ring with heterocycles.

D. Rohrer, K. Marotti, A. Thorarensen, 2007, Bioorganic & medicinal chemistry letters.

Potent and Selective TYK2-JH1 Inhibitors Highly Efficacious in Rodent Model of Psoriasis.

Markus K. Dahlgren, J. McElwee, Mee Shelley, 2022, Bioorganic & medicinal chemistry letters.

Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) structure and biochemistry reveals remarkable similarities to HIV-1 RT and opportunities for HERV-K–specific inhibition

S. Steinbacher, E. Arnold, M. Lamers, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-88204E.

J. Chou, A. Gonzales, D. Romero, 1993, Biochemistry.

Spectroscopic studies of delavirdine mesylate (U-90,152T) a bis(heteroaryl)piperazine (BHAP) HIV reverse transcriptase inhibitor

G. S. Walker, R. H. Robins, J. Gage, 1996 .

A stereoselective intramolecular 1,3-dipolar nitrone cycloaddition for the synthesis of substituted chromanes.

Qian Zhao, D. Romero, Fusen Han, 2002, The Journal of organic chemistry.

Resistance mapping and mode of action of a novel class of antibacterial anthranilic acids: evidence for disruption of cell wall biosynthesis.

K. Marotti, D. Romero, J. Mott, 2008, The Journal of antimicrobial chemotherapy.

Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E.

J. Chou, A. Gonzales, D. Romero, 1993, The Journal of biological chemistry.

Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives.

S. Swaney, D. Romero, C. Biles, 2000, Journal of medicinal chemistry.

Pd-Catalyzed Cycloisomerization to 1,2-Dialkylidenecycloalkanes. 2. Alternative Catalyst System

B. Trost, F. Rise, D. Romero, 1994 .

Preparation of novel anthranilic acids as antibacterial agents. Extensive evaluation of alternative amide bioisosteres connecting the A- and the B-rings.

D. Rohrer, K. Marotti, A. Thorarensen, 2007, Bioorganic & medicinal chemistry letters.

The solid phase synthesis of tetrahydroisoquinolines having cdc25B inhibitory activity.

E. Fritzen, D. Romero, L. Erickson, 2000, Bioorganic & medicinal chemistry letters.

Methoxy(phenylthio)methane

D. Romero, 2001 .

A novel method for the t-butylation of aromatic amines

D. Romero, C. Biles, M. Genin, 1993 .

Design and synthesis of a conformationally constrained analog of the bis(heteroaryl)piperazine (BHAP) HIV-1 reverse transcriptase inhibitor atevirdine

D. Rohrer, D. Romero, C. Chidester, 1995 .

The palladium catalyzed allylic alkylation of bis(trimethylsilyl) substituted propenyl acetates or carbonates in the presence of chiral ligands

E. Fritzen, D. Romero, 1997 .

Human serum albumin binding assay based on displacement of a non selective fluorescent inhibitor.

K. Marotti, A. Thorarensen, D. Romero, 2007, Bioorganic & medicinal chemistry letters.

Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.

Joel Morris, D. B. Evans, S. Sharma, 1996, Journal of medicinal chemistry.

Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors.

H. Lane, D. Romero, N. Salzman, 1992, Virology.

The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase.

L. Resnick, D. Romero, I W Althaus, 1996, Biochemical pharmacology.

Discovery and development of the BHAP nonnucleoside reverse transcriptase inhibitor delavirdine mesylate.

R. Jensen, D. Romero, W. Morozowich, 1998, Pharmaceutical biotechnology.

Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E.

J. Chou, A. Gonzales, D. Romero, 1994, Biochemical pharmacology.

(Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes

K. Rank, L. Kopta, R. Olmsted, 1996, Journal of virology.

Human T cells are highly sensitive to suppression of mitogenesis by polycyclic aromatic hydrocarbons and this effect is differentially reversed by alpha-naphthoflavone.

S. Burchiel, D. Romero, D. R. Davila, 1996, Toxicology and applied pharmacology.

Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.

R. F. Campbell, M. Gurney, J. O'Donnell, 2019, Journal of medicinal chemistry.

Steady-state kinetic studies with the polysulfonate U-9843, an HIV reverse transcriptase inhibitor

J. J. Chou, J. Chou, A. Gonzales, 1994, Experientia.

The quinoline U-78036 is a potent inhibitor of HIV-1 reverse transcriptase.

L. Resnick, J. Chou, A. Gonzales, 1993, The Journal of biological chemistry.

Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy

L. Staudt, A. Shaffer, L. Rui, 2015, The Journal of experimental medicine.

Asymmetric Synthesis of the C3alpha Fragment of 5,6-Dihydro-alpha-pyrone Nonpeptidic HIV-1 Protease Inhibitors.

D. Romero, Fusen Han, A. Romero, 1999, The Journal of organic chemistry.

IRAK4 Kinase As A Novel Therapeutic Target in the ABC Subtype of Diffuse Large B Cell Lymphoma

L. Staudt, K. Lim, S. Robinson, 2012 .

Bacterial translation inhibitors, 1-acylindazol-3-ols as anthranilic acid mimics.

D. Rohrer, K. Marotti, A. Thorarensen, 2008, Bioorganic & medicinal chemistry letters.

Discovery and initial development of a novel class of antibacterials: inhibitors of Staphylococcus aureus transcription/translation.

K. Marotti, D. Romero, M. T. Sweeney, 2006, Bioorganic & medicinal chemistry letters.

Effect Of MYD88 Mutation In CLL On IRAK4 and BTK Inhibition In Vitro

N. Pochet, D. Neuberg, R. Improgo, 2013 .

Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279.

J. McElwee, Phani Ghanakota, Wenyan Miao, 2023, Journal of Medicinal Chemistry.

PAS kinase drives lipogenesis through SREBP-1 maturation.

J. Rutter, D. Romero, J. Blitzer, 2014, Cell reports.